<DOC>
	<DOCNO>NCT02050815</DOCNO>
	<brief_summary>This study phase I , multi-center , open-label , single oral dose , parallel group study assess PK safety MEK162 subject impair hepatic function healthy subject normal hepatic function . Subjects assign hepatic function define elevation serum total bilirubin serum AST determine screen baseline visit . The study population healthy male postmenopausal sterile female subject meet inclusion none exclusion criterion . A minimum 24 evaluable subject ( 6 subject per group ) enrol . The group : Group 1-healthy volunteer , Group 2-Mild hepatic impairment , Group 3-Moderate hepatic impairment Group 4-Severe hepatic impairment . Once approved enrollment , participant confine facility 5 day , give single dose MEK162 monitor safety assessment , labs PK assess .</brief_summary>
	<brief_title>MEK162 Healthy Subjects With Normal Hepatic Function Subjects With Impaired Hepatic Function</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Written inform consent prior screen procedure Male female ( postmenopausal sterilize ) Subject body weight least 45 kg body mass index ( BMI ) range 18 35.0 kg/m2 Subjects normal hepatic function must total bilirubin ≤ upper limit normal ( ≤ ULN ) , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , gammaglutamyl transferase ( GGT ) alkaline phosphatase ( AP ) ≤ ULN , serum creatinine ≤ ULN , serum amylase lipase ≤ ULN Additional inclusion criterion subject abnormal liver function determine elevation serum total bilirubin : Absolute neutrophil count ( ANC ) &gt; 1000 cell/mm3 Hb &gt; 9 mg/dl , Platelet count &gt; 30,000/mm3 Serum creatinine ≤ 1.8 mg/dl Otherwise consider healthy free significant medical disorder unrelated subject 's hepatic disorder Women childbearing potential Pregnant nursing ( lactate ) woman Subjects impair cardiovascular function clinically significant cardiovascular disease Uncontrolled arterial hypertension despite medical treatment History current evidence retinal vein occlusion ( RVO ) current risk factor RVO ( e.g . uncontrolled glaucoma ocular hypertension , history hyperviscosity hypercoagulability syndrome ) , History Gilbert 's syndrome Immunocompromised subject ( include know history/seropositivity HIV ) Any surgical medical condition ( hepatic impairment ) receive pharmacological treatment might significantly alter absorption metabolism drug may jeopardize subject case participation study Antecedent malignancy follow exception : adequately treat basal cell squamous cell carcinoma skin Subjects neuromuscular disorder associate elevated CK ( e.g. , inflammatory myopathy , muscular dystrophy , amyotrophic lateral sclerosis , spinal muscular atrophy ) Subjects undergone major surgery ≤ 3 week prior start study drug recover side effect procedure History clinically significant drug allergy Prior therapy MEKinhibitor Use investigational drug within 30 day screen Current smoker use tobacco product product contain nicotine within 7 day prior dose study drug Consumption alcohol within 3 day prior dose study Additional exclusion criterion subject normal hepatic function : Clinical evidence liver disease liver injury indicate abnormal liver function test ALT , AST , GGT , alkaline phosphatase , serum bilirubin . ALT AST beyond normal range inclusion Presence impair renal function indicate abnormal creatinine ( creatinine clearance &lt; 80 mL/min ) value and/or serum creatinine ≥1.8 mg/dL A positive Hepatitis B Hepatitis C test result Additional exclusion criterion subject elevation serum bilirubin &gt; UNL : Symptoms history encephalopathy ( Grade II worse ) within 4 week study entry Clinical evidence severe ascites require intervention International normalize ratio ( INR ) &gt; 2.5 Any evidence progressive liver disease within last 3 week prior screen visit ) indicate worsen clinical manifestation ( i.e . : ascites , encephalopathy ) and/or laboratory abnormality ( liver transaminase , alkaline phosphatase GGT ≥ 50 % worsen serum bilirubin prothrombin time ) History surgical portosystemic shunt complication ( i.e . hepatic encephalopathy , heart failure ) Active bleed last 28 day prior dose include variceal bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MEK162</keyword>
	<keyword>Hepatic impairment</keyword>
	<keyword>Healthy subject</keyword>
</DOC>